Exclusive Summary

• - Both actives are legacy molecules and the fixed-dose combo (historical brand Pevisone) is long off‑patent globally, enabling fast multi‑country entry.\n- Superficial mycoses affect ~20–25% of the world population; the combo addresses clear needs for rapid itch/inflammation relief in highly inflamed cases.\n- Multi‑pharmacopoeial compliance (JP/BP/USP/EP/KP) plus TT/Distribution options support broad registrations and local manufacturing (note: no China‑agency for Vietnam).\n- Not approved as an FDC in the US and tightened use in parts of the EU, but widely accepted across Asia/LatAm/Africa/MENA with room for channel and packaging differentiation.\n- Versus legacy brands/imports, generics typically achieve ~60–90% price reductions, fitting both retail self‑pay and public procurement strategies.